A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth Linea Aspesi Linea Aspesi BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Ex
TRDA stock fell over 15% after Entrada Therapeutics announced initial Phase 1/2 ELEVATE-45-201 study results for ENTR-601-45.
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and function
Entrada Therapeutics (ENTR) Buy call: $8.50 fair value (~52% upside). Valuation is anchored by risk-adjusted pipeline estimates. See more details here.
This is the newest page. Registered accounts read further back.